Polskie Radio covers the FDA clearing Lilly's Zepbound to treat obstructive sleep apnea, an earlier approval beyond weight loss.
Recap by typeshit. Full story at www.polskieradio.pl.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
13:00
A short video on what else people may be losing besides fat while on tirzepatide, a point raised often around muscle loss on GLP-1 drugs.
In 2,749 adults with type 2 diabetes and high heart risk, Lilly's pill had fewer heart events and less low blood sugar, but GI side effects hit 62% of users.
Loading…